Opportunity ID: 320196

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-19-364
Funding Opportunity Title: Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.855 — Allergy and Infectious Diseases Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Sep 03, 2019
Last Updated Date: Sep 03, 2019
Original Closing Date for Applications: Jan 10, 2022
Current Closing Date for Applications: Jan 10, 2022
Archive Date: Feb 15, 2022
Estimated Total Program Funding:
Award Ceiling: $200,000
Award Floor:

Eligibility

Eligible Applicants: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Small businesses
Independent school districts
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Native American tribal governments (Federally recognized)
County governments
Private institutions of higher education
For profit organizations other than small businesses
City or township governments
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
State governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical and preclinical/non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-19-364.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email: FBOWebmaster@OD.NIH.GOV
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-F Use for due dates on or before January 24, 2022 PKG00259752 Dec 06, 2019 Jan 24, 2022 View
FORMS-E Use for due dates on or before May 24, 2020 PKG00254503 Dec 06, 2019 May 24, 2020 View
FORMS-G Use for due dates on or after January 25, 2022 PKG00270247 Nov 16, 2021 Jan 10, 2022 View

Package 1

Mandatory forms

320196 RR_SF424_2_0-2.0.pdf

320196 PHS398_CoverPageSupplement_5_0-5.0.pdf

320196 RR_OtherProjectInfo_1_4-1.4.pdf

320196 PerformanceSite_2_0-2.0.pdf

320196 RR_KeyPersonExpanded_2_0-2.0.pdf

320196 PHS398_ResearchPlan_4_0-4.0.pdf

320196 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

320196 RR_Budget_1_4-1.4.pdf

320196 RR_SubawardBudget30_1_4-1.4.pdf

320196 PHS398_ModularBudget_1_2-1.2.pdf

320196 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 2

Mandatory forms

320196 RR_SF424_2_0-2.0.pdf

320196 PHS398_CoverPageSupplement_4_0-4.0.pdf

320196 RR_OtherProjectInfo_1_4-1.4.pdf

320196 PerformanceSite_2_0-2.0.pdf

320196 RR_KeyPersonExpanded_2_0-2.0.pdf

320196 PHS398_ResearchPlan_4_0-4.0.pdf

Optional forms

320196 RR_Budget_1_4-1.4.pdf

320196 RR_SubawardBudget30_1_4-1.4.pdf

320196 PHS398_ModularBudget_1_2-1.2.pdf

320196 PHS_AssignmentRequestForm_2_0-2.0.pdf

Package 3

Mandatory forms

320196 RR_SF424_5_0-5.0.pdf

320196 PHS398_CoverPageSupplement_5_0-5.0.pdf

320196 RR_OtherProjectInfo_1_4-1.4.pdf

320196 PerformanceSite_4_0-4.0.pdf

320196 RR_KeyPersonExpanded_4_0-4.0.pdf

320196 PHS398_ResearchPlan_4_0-4.0.pdf

320196 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

320196 RR_Budget_3_0-3.0.pdf

320196 RR_SubawardBudget30_3_0-3.0.pdf

320196 PHS398_ModularBudget_1_2-1.2.pdf

320196 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-09T08:48:01-05:00

Share This Post, Choose Your Platform!

About the Author: